Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizuma

Journal of Clinical Oncology

Volumn 29, Issue 11, 2011, Pages

  Fellah, Slim ^a   Girard, Nadine ^a   Chinot, Olivier ^a   Cozzone, Patrick J ^a   Callot, Virginie ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CASE REPORT; GLIOBLASTOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPIN LABELING; SUSCEPTIBILITY WEIGHTED IMAGING; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 79955008477     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.6082     Document Type: Article

References (19)

1. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
2. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
3. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007 (Pubitemid 350086473)
4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007 (Pubitemid 46424067)
5. van den Bent MJ, Vogelbaum MA, Wen PY, et al: End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 27:2905-2908, 2009
6. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972, 2010
7. Detre JA, Alsop DC: Perfusion magnetic resonance imaging with continuous arterial spin labeling: Methods and clinical applications in the central nervous system. Eur J Radiol 30:115-124, 1999 (Pubitemid 29281712)
8. Detre JA, Leigh JS, Williams DS, et al: Perfusion imaging. Magn Reson Med 23:37-45, 1992
9. Reference deleted
10. Warmuth C, Gunther M, Zimmer C: Quantification of blood flow in brain tumors: Comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 228:523-532, 2003 (Pubitemid 36910097)
11. Gaa J, Warach S, Wen P, et al: Noninvasive perfusion imaging of human brain tumors with EPISTAR. Eur Radiol 6:518-522, 1996 (Pubitemid 126462816)
12. Weber MA, Thilmann C, Lichy MP, et al: Assessment of irradiated brain metastases by means of arterial spin-labeling and dynamic susceptibilityweighted contrast-enhanced perfusion MRI: Initial results. Invest Radiol 39:277-287, 2004 (Pubitemid 38520662)
13. Reichenbach JR, Venkatesan R, Schillinger DJ, et al: Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 204:272-277, 1997 (Pubitemid 27281745)
14. Haacke EM, Mittal S, Wu Z, et al: Susceptibility-weighted imaging: Technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 30:19-30, 2009
15. Sehgal V, Delproposto Z, Haacke EM, et al: Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 22:439-450, 2005 (Pubitemid 41416402)
16. Mittal S, Wu Z, Neelavalli J, et al: Susceptibility-weighted imaging: Technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 30:232-252, 2009
17. Sehgal V, Delproposto Z, Haddar D, et al: Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 24:41-51, 2006
18. Park MJ, Kim HS, Jahng GH, et al: Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: Comparison with MR perfusion imaging. AJNR Am J Neuroradiol 30:1402-1408, 2009
19. Jain R, Scarpace LM, Ellika S, et al: Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96:423-431, 2010